Joseph Sharpe
Psychiatry · Nashville, TNNPI 1508863929
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (48.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Neuronetics, Inc. at 49.0% of the total. 2025 is the largest year on record at $15,152, 2.1 times the $7,363 reported in 2019. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $145.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$14K
- Johnson & Johnson$6K
- Corium, LLC$5K
- AbbVie$712
- Lundbeck LLC$570
- Otsuka America Pharmaceutical, Inc.$483
- plus $2K from 15 others
What the payments were for
- Consulting fees$7202%
- Speaking & faculty fees$8,11028%
- Travel & lodging$1,1174%
- Food & beverage$4,94317%
- Education$300%
- Other$14,20349%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 4 | $14,277 |
| Johnson & Johnson | 17 | $6,236 |
| Corium, LLC | 27 | $4,572 |
| AbbVie(2 entities) | 35 | $712 |
| Lundbeck LLC | 27 | $570 |
| Otsuka America Pharmaceutical, Inc. | 18 | $483 |
| Livanova USA, Inc. | 3 | $403 |
| Jazz Pharmaceuticals Inc. | 15 | $315 |
| Ironshore Pharmaceuticals Inc. | 6 | $312 |
| Alkermes, Inc. | 12 | $243 |
| Sunovion Pharmaceuticals Inc. | 8 | $162 |
| Axsome Therapeutics, Inc. | 6 | $150 |
| E.r. Squibb & Sons, L.L.C. | 2 | $145 |
| Eisai Inc. | 2 | $141 |
| Teva Pharmaceuticals USA, Inc. | 3 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $105 |
| Tris Pharma Inc | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Vertical Pharmaceuticals, LLC | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$14,203
- SPRAVATO$5,932
- Azstarys$4,080
- VNS Therapy Symmetry Model 8103 Generator$320
- Jornay PM 20mg capsules (Bottle of 100)$153
- COBENFY$122
- Dayvigo$120
- SUNOSI$118
- AUSTEDO$113
- REXULTI$108
- VRAYLAR$108
How this compares
$29,123 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 11 | $14,961 |
| FetzimaLevomilnacipran Hcl | 12 | $5,642 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 43 | $2,114 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $1,530 |
| Aripiprazole | 16 | $1,161 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 33 | $1,123 |
| Duloxetine Hcl | 41 | $1,067 |
| Bupropion XlBupropion Hcl | 24 | $588 |
| Lurasidone Hcl | 12 | $566 |
| Trazodone Hcl | 62 | $499 |
| Quetiapine Fumarate | 54 | $401 |
| Lamotrigine | 30 | $284 |
| Clonazepam | 58 | $282 |
| Mirtazapine | 15 | $251 |
| Pregabalin | 24 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $712 | $20,60323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Nashville
- Rakesh AminNashville$3M
- Robert JamiesonNashville$141K
- Michelle CochranNashville$74K
- Amanda Sparks-BushnellNashville$66K
- Craig ClarkNashville$31K
- Colleen FriddellNashville$23K
- Jane WeinbergNashville$22K
- Esiri EsinNashville$18K
- Tianlai TangNashville$11K
- Marianne RaynesNashville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.